CRES 101
Alternative Names: BDX-101; CRES-101Latest Information Update: 06 May 2024
At a glance
- Originator Cresence
- Developer biOasis Technologies
- Class Neuropeptides; Neuroprotectants
- Mechanism of Action Myelin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Optic neuritis
Most Recent Events
- 20 Jun 2023 Discontinued - Phase-I for Chronic inflammatory demyelinating polyradiculoneuropathy in Norway (unspecified route) before June 2023
- 20 Jun 2023 Discontinued - Phase-I for Guillain-Barre syndrome in Norway (unspecified route) before June 2023
- 20 Jun 2023 Discontinued - Phase-I for Optic neuritis in Norway (unspecified route) before June 2023